1 active not recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Relapsing-remitting Multiple Sclerosis (RRMS): new trials by email Literature Review of Relapsing-remitting Multiple Sclerosis (RRMS) trials Research Report on Relapsing-remitting Multiple Sclerosis (RRMS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis Rocbrutinib, Dimethyl Fumarate - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 30 | 2026-08-01 | 2026-08-20 |
| MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) IMU-838 (30 mg/day), IMU-838 (45 mg/day), Placebo - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 2 | Active not recruiting | Immunic AG | 210 | 2019-01-28 | 2024-04-24 |
Multiple Sclerosis (2) · Multiple Sclerosis, Relapsing-Remitting (2)
Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Autoimmune Diseases, CNS (2) · Demyelinating Diseases (2) · Immune System Diseases (2) · Nervous System Diseases (2)
Dimethyl Fumarate (1) · Tablets (1)
Guangzhou Lupeng Pharmaceutical Company LTD. (1) · Immunic AG (1)
Bulgaria (1) · China (1) · Poland (1) · Romania (1) · Ukraine (1)
Andreas Muehler (1) · De-Cai Tian, M.D., Ph.D. (1)
2018 (1)